Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

featured

Published in Oncology

Expert Opinion / Interview · July 30, 2018

Durvalumab as Late Stage Treatment of NSCLC: Relationship With EGFR, ALK and PD-L1 Positivity—A West Cancer Center Perspective

Interview with: David C Portnoy MD
Interview questions written by: Erin Schenk MD, PhD

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Additional Info

Related Items

Durvalumab as Third-Line or Later Treatment for Advanced Non–Small Cell Lung Cancer

featured

Afamitresgene Autoleucel for Advanced Synovial Sarcoma and Myxoid Round Cell Liposarcoma

Lancet · April 18, 2024
featured

First-Line Sintilimab With Pegaspargase, Gemcitabine, and Oxaliplatin for Advanced Extranodal Natural Killer/T-Cell Lymphoma

Lancet Haematol · April 17, 2024
featured

Pembrolizumab Plus Concurrent Chemoradiotherapy for Locally Advanced HNSCC

Lancet Oncol · April 17, 2024
featured

Preoperative Durvalumab or Durvalumab Plus Tremelimumab for Resectable HNSCC

Clin. Cancer Res · April 16, 2024

updated
story of the week

Pembrolizumab With Chemoradiotherapy Followed by Pembrolizumab for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer

Lancet · April 16, 2024

updated
story of the week

Association Between Chronic Stress and Metastasis in Patients With Cancer

Cancer Cell · April 16, 2024
featured

Once-Weekly vs Twice-Weekly Bortezomib for Newly Diagnosed Multiple Myeloma

Blood Cancer J · April 11, 2024

updated
featured

Anti-CD19 CAR T-Cell Therapy for Richter Transformation

J. Clin. Oncol · April 11, 2024
featured

ASCO Guidelines on Cannabis and Cannabinoid Use in Adults With Cancer

J. Clin. Oncol · April 09, 2024
story of the week

Long-Term Follow-Up of Mosunetuzumab in Patients With Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas

J. Clin. Oncol · April 09, 2024
featured

Impact of Initial Tumor Response on Survival Outcomes in Patients With HER2+ Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab

Clin. Breast Cancer · April 08, 2024

Durvalumab as Late Stage Treatment of NSCLC: Relationship With EGFR, ALK and PD-L1 Positivity—A West Cancer Center Perspective

Additional Info

Further Reading

Afamitresgene Autoleucel for Advanced Synovial Sarcoma and Myxoid Round Cell Liposarcoma

First-Line Sintilimab With Pegaspargase, Gemcitabine, and Oxaliplatin for Advanced Extranodal Natural Killer/T-Cell Lymphoma

Pembrolizumab Plus Concurrent Chemoradiotherapy for Locally Advanced HNSCC

Preoperative Durvalumab or Durvalumab Plus Tremelimumab for Resectable HNSCC

Pembrolizumab With Chemoradiotherapy Followed by Pembrolizumab for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer

Association Between Chronic Stress and Metastasis in Patients With Cancer

Once-Weekly vs Twice-Weekly Bortezomib for Newly Diagnosed Multiple Myeloma

Anti-CD19 CAR T-Cell Therapy for Richter Transformation

ASCO Guidelines on Cannabis and Cannabinoid Use in Adults With Cancer

Long-Term Follow-Up of Mosunetuzumab in Patients With Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas

Impact of Initial Tumor Response on Survival Outcomes in Patients With HER2+ Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab

Related Videos